PIRS vs. IFRX, LFVN, CASI, CRVO, IOBT, BNTC, PMVP, CLRB, CLSD, and ASMB
Should you be buying Pieris Pharmaceuticals stock or one of its competitors? The main competitors of Pieris Pharmaceuticals include InflaRx (IFRX), LifeVantage (LFVN), CASI Pharmaceuticals (CASI), CervoMed (CRVO), IO Biotech (IOBT), Benitec Biopharma (BNTC), PMV Pharmaceuticals (PMVP), Cellectar Biosciences (CLRB), Clearside Biomedical (CLSD), and Assembly Biosciences (ASMB). These companies are all part of the "pharmaceutical preparations" industry.
Pieris Pharmaceuticals (NASDAQ:PIRS) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.
Pieris Pharmaceuticals has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.
InflaRx has a consensus price target of $13.50, indicating a potential upside of 782.35%. Given InflaRx's higher possible upside, analysts clearly believe InflaRx is more favorable than Pieris Pharmaceuticals.
Pieris Pharmaceuticals received 43 more outperform votes than InflaRx when rated by MarketBeat users. However, 64.38% of users gave InflaRx an outperform vote while only 60.83% of users gave Pieris Pharmaceuticals an outperform vote.
Pieris Pharmaceuticals has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Pieris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Pieris Pharmaceuticals had 9 more articles in the media than InflaRx. MarketBeat recorded 11 mentions for Pieris Pharmaceuticals and 2 mentions for InflaRx. InflaRx's average media sentiment score of 1.44 beat Pieris Pharmaceuticals' score of 0.31 indicating that InflaRx is being referred to more favorably in the news media.
InflaRx has a net margin of 0.00% compared to Pieris Pharmaceuticals' net margin of -39.71%. InflaRx's return on equity of -37.37% beat Pieris Pharmaceuticals' return on equity.
40.1% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 8.9% of Pieris Pharmaceuticals shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
InflaRx beats Pieris Pharmaceuticals on 12 of the 18 factors compared between the two stocks.
Get Pieris Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PIRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pieris Pharmaceuticals Competitors List
Related Companies and Tools
